About this event:
JN Nova Pharma (https://jnnova.com/) is the co-development partner with NRC-Human Health Therapeutics to bring a therapeutic biomolecule class to the clinic which traps all known, and likely future, COVID-19 viral variants. This inhalation therapeutic product has a mechanism which goes beyond viral trapping: By giving full ACE2 enzyme replacement, it provides a unique protective role to the lungs from the acute respiratory distress syndrome (ARDS) and longer-term lung injuries, leading to Pulmonary Fibrosis which result from ACE2 loss by severe viral infection. Our therapeutic candidate will enter the clinic in Q2, 2023, it is delivered as an inhaled aerosol and is easily administered to COVID patients and to treat long-haul/recovery COVID patients. Based on its pan-viral trapping it could be stockpiled against any future COVID variants and provide future pandemic preparedness.
Due to limited space, registration will be on a first-come-first-serve basis.
Dr. John Gillard is one of Canada’s precision medicine biotech pioneers. Chief Product Development Officer at JN Nova Pharma. He gained his PhD in Australia and did post doctoral fellowships at CNRS Paris and Harvard University, Boston. Having completed a successful early career as Director of Medicinal Chemistry at Merck Research Laboratories in Montreal, from which the highly successful anti-asthma drug, Singulair was developed, he joined BioChem Pharma. There he recruited and directed the very successful team of scientists responsible for the discovery and development of the landmark anti-viral drugs lamivudine (3TC) for HIV and Zeffix (Epivir) for hepatitis B, and led several successful multinational collaborations with Glaxo, Astra and Pfizer. BioChem Pharma was subsequently acquired by Shire for >$5B.
6:00 – 6:30 pm Welcome + buffet style dinner + drinks + network
6:30 – 7:15 pm Presentation + Q&A
7:15 – 8:00 pm Network + Conclusion